Assessment of Healthcare Resource Utilization by Anticoagulant Heparinoid Dosage Level in Patients Hospitalized with COVID-19

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2022 Nov 14

PMID 36373759

Authors

Keith Robinson

Laura L Schott

Tom Matthews

Manu Tyagi

Vivek B Ajmani

Nancy Sacco

Zhun Cao

Affiliations

Soon will be listed here.

Abstract

The aim was to describe inpatients with COVID-19 empirically prescribed heparinoid anticoagulants and compare resource utilization between prophylactic/low-dose and therapeutic/high-dose groups. This retrospective observational study used real-world data from 880 US hospitals in the PINC AI™ Healthcare Database during 4/1/2020-11/30/2020. Descriptive analysis was used to characterize patients. Multivariable regression was used to evaluate intensive care unit (ICU) admissions, length of stay (LOS), mortality, and costs by anticoagulation dose group, adjusting for cohort characteristics. Among 122,508 inpatients, 29,225 (23.9%) received therapeutic/high-dose, and 93,283 (76.1%) received prophylactic/low-dose anticoagulation. The high-dose group had more comorbidities and worse laboratory values compared with low-dose. Respectively, ICU admission rates were 36.7% and 19.1% and LOS median (Q1, Q3) was 8 (5, 15) and 5 (3, 9) days. In separate adjusted models, high-dose anticoagulation was associated with a 45% increase in odds of ICU admission, 26% increase in odds of in-hospital mortality, 21% longer average LOS, and 28% greater average total cost compared with low-dose (each 0.001). Prophylactic/low-dose anticoagulation treatment was associated with decreased healthcare resource utilization (HRU) in hospitalized patients with COVID-19.

References

Anderson M, Bach P, Baldwin M . Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value. Pharmacoecon Open. 2020; 5(1):129-131. PMC: 7734451. DOI: 10.1007/s41669-020-00243-6. View

Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati M, Iacoviello L . Different Anticoagulant Regimens, Mortality, and Bleeding in Hospitalized Patients with COVID-19: A Systematic Review and an Updated Meta-Analysis. Semin Thromb Hemost. 2021; 47(4):372-391. DOI: 10.1055/s-0041-1726034. View

Samama M, Cohen A, Darmon J, Desjardins L, Eldor A, Janbon C . A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999; 341(11):793-800. DOI: 10.1056/NEJM199909093411103. View

Miesbach W, Makris M . COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clin Appl Thromb Hemost. 2020; 26:1076029620938149. PMC: 7370334. DOI: 10.1177/1076029620938149. View

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S . Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7):934-943. PMC: 7070509. DOI: 10.1001/jamainternmed.2020.0994. View

Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo P, Cuapio A . More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021; 11(1):16144. PMC: 8352980. DOI: 10.1038/s41598-021-95565-8. View

Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg B, Levin M . Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020; 76(1):122-124. PMC: 7202841. DOI: 10.1016/j.jacc.2020.05.001. View

Lawler P, Goligher E, Berger J, Neal M, McVerry B, Nicolau J . Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021; 385(9):790-802. PMC: 8362594. DOI: 10.1056/NEJMoa2105911. View

Xiong X, Chi J, Gao Q . Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis. Thromb J. 2021; 19(1):32. PMC: 8132033. DOI: 10.1186/s12959-021-00284-9. View

10.

Huang W, Anderson F, Rushton-Smith S, Cohen A . Impact of thromboprophylaxis across the US acute care setting. PLoS One. 2015; 10(3):e0121429. PMC: 4376674. DOI: 10.1371/journal.pone.0121429. View

11.

Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

12.

Kasinathan G, Sathar J . Haematological manifestations, mechanisms of thrombosis and anti-coagulation in COVID-19 disease: A review. Ann Med Surg (Lond). 2020; 56:173-177. PMC: 7324342. DOI: 10.1016/j.amsu.2020.06.035. View

13.

Pawlowski C, Venkatakrishnan A, Kirkup C, Berner G, Puranik A, OHoro J . Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. EClinicalMedicine. 2021; 33:100774. PMC: 7941023. DOI: 10.1016/j.eclinm.2021.100774. View

14.

Giannis D, Allen S, Tsang J, Flint S, Pinhasov T, Williams S . Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry. Blood. 2021; 137(20):2838-2847. PMC: 8032474. DOI: 10.1182/blood.2020010529. View

15.

Coppock D, Baram M, Chang A, Henwood P, Kubey A, Summer R . COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. PLoS One. 2021; 16(6):e0252591. PMC: 8195431. DOI: 10.1371/journal.pone.0252591. View

16.

Moon R, Mackey R, Cao Z, Emont S, Schott L, Gayle J . Is Coronavirus Disease 2019 (COVID-19) Less Deadly Now? Trends in In-Hospital Mortality Among Hospitalized COVID-19 Patients in the United States. Clin Infect Dis. 2021; 74(12):2238-2242. PMC: 8522416. DOI: 10.1093/cid/ciab830. View

17.

Nadkarni G, Lala A, Bagiella E, Chang H, Moreno P, Pujadas E . Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020; 76(16):1815-1826. PMC: 7449655. DOI: 10.1016/j.jacc.2020.08.041. View

18.

Fowler R, Mittmann N, Geerts W, Heels-Ansdell D, Gould M, Guyatt G . Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. JAMA. 2014; 312(20):2135-45. DOI: 10.1001/jama.2014.15101. View

19.

Guo A, Lu J, Tan H, Kuang Z, Luo Y, Yang T . Risk factors on admission associated with hospital length of stay in patients with COVID-19: a retrospective cohort study. Sci Rep. 2021; 11(1):7310. PMC: 8012638. DOI: 10.1038/s41598-021-86853-4. View

20.

Atallah B, Mallah S, Almahmeed W . Anticoagulation in COVID-19. Eur Heart J Cardiovasc Pharmacother. 2020; 6(4):260-261. PMC: 7197600. DOI: 10.1093/ehjcvp/pvaa036. View